View original post here:
Frontier Medicines Announces FMC-220, the First Covalent p53 Y220C Activator Development Candidate, with Best-in-Class Potential
Related Post
- Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates - January 9th, 2025
- Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy - January 9th, 2025
- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders - January 9th, 2025
- Ribometrix Strengthens Leadership, Appoints William S. Marshall, Ph.D., as Chief Executive Officer and Katie Warner, Ph.D., as Chief Scientific... - January 9th, 2025
- Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones - January 9th, 2025
- Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference - January 9th, 2025
- TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - January 9th, 2025
- ElevateBio to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 9th, 2025
- RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 9th, 2025
- Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including... - January 9th, 2025
- Ori Biotech Expands Team to Advance IRO Commercialization and Industry Partnerships - January 9th, 2025
- IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as... - January 9th, 2025
- Alkeus Pharmaceuticals Announces New Positive Interim TEASE-3 Study Results Showing Gildeuretinol Prevented Disease Progression in Early-Stage... - January 9th, 2025
- Biosphere Launches UV Bioreactor to Transform Industrial Fermentation - January 9th, 2025
- FYR Appoints Chris Howlett to its Board of Directors - January 9th, 2025
- Inmagene Reports Positive Topline Results of IMG-007, a Nondepleting Anti-OX40 Monoclonal Antibody with an Extended Half-Life, for the Treatment of... - January 9th, 2025
- CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders - January 9th, 2025
- BioLizard Welcomes Arjan van Manen as Commercial Director and Announces Presence at JPM Week in San Francisco - January 9th, 2025
- Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference - January 9th, 2025
- ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease - January 7th, 2025
- Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference - January 7th, 2025
- Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference - January 7th, 2025
- CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update - January 7th, 2025
- Oncocyte Expands Market Opportunity for VitaGraft™ Kidney - January 7th, 2025
- Lifecore Biomedical to Participate at 43rd Annual J.P. Morgan Healthcare Conference - January 7th, 2025
- Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases - January 7th, 2025
- ORIC® Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 7th, 2025
- Kura Oncology Announces Senior Executive Promotions - January 7th, 2025
- Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 7th, 2025
- Umoja Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 7th, 2025
- Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference - January 7th, 2025
- Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial - January 7th, 2025
- Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA - January 7th, 2025
- Zhengye Biotechnology Holding Limited Announces Pricing of Initial Public Offering - January 7th, 2025
- Orion’s collaboration partner Bayer submits application in China for third indication of darolutamide - January 7th, 2025
- Pentixapharm Receives EUR 6.77 Million for Intangible Assets Formerly Developed by Glycotope - January 7th, 2025
- Interius BioTherapeutics Announces Regulatory Approval to Expand Phase 1 Clinical Trial of INT2104 into Europe - January 7th, 2025
- Biodesix Announces Publication of a New Nodify CDT® Clinical Validation Study - January 7th, 2025
- Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights - January 7th, 2025
- Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 3rd, 2025
- Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development - January 3rd, 2025
- Atavistik Bio Announces Research Collaboration with Pfizer to Accelerate Discovery of Novel Precision Allosteric Therapeutics - January 3rd, 2025
- TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses - January 3rd, 2025
- Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office - January 3rd, 2025
- Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - January 3rd, 2025
- Cytek Biosciences to present at the 43rd Annual J.P. Morgan Healthcare Conference - January 3rd, 2025
- Lexicon Appoints Scott Coiante as Chief Financial Officer - January 3rd, 2025
- Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners - January 3rd, 2025
- SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 am ET - January 3rd, 2025
- Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain - January 3rd, 2025
- Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular... - January 3rd, 2025
- Pacira BioSciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 3rd, 2025
- PacBio to Present at 43rd Annual J.P. Morgan Healthcare Conference - January 3rd, 2025
- Seer to Present at the J.P. Morgan 43rd Annual Healthcare Conference - January 3rd, 2025
- Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 3rd, 2025
- Lifecore Biomedical Reports Second Quarter Fiscal 2025 Financial Results and Provides Corporate Update - January 3rd, 2025
- Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - January 3rd, 2025
- Tilray Brands Moves Earnings Date to January 10, 2025, in Observance of the National Day of Mourning - January 3rd, 2025
- ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab - January 3rd, 2025
- Park Ha Biological Technology Co., Ltd. Announces Closing of $4.8 Million Initial Public Offering - January 1st, 2025
- Galera Therapeutics completes acquisition of Nova Pharmaceuticals - January 1st, 2025
- Burning Rock Announces Results of 2024 Annual General Meeting - January 1st, 2025
- Spectral AI Provides Instructions for Retail Investors on Exercising Publicly-Traded Warrants - January 1st, 2025
- Oncotelic Therapeutics Implements PDAOAI Platform - January 1st, 2025
- Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344 - January 1st, 2025
- Firefly Neuroscience Closes on Financing of up to $12.4 Million - January 1st, 2025
- Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA - January 1st, 2025
- SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder - January 1st, 2025
- HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture - January 1st, 2025
- European Commission approves RYBREVANT®▼ (amivantamab) in combination with LAZCLUZE®▼ (lazertinib) for the first-line treatment of patients with... - December 30th, 2024
- Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA - December 30th, 2024
- Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging - December 30th, 2024
- Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies - December 30th, 2024
- Orion and Marinus terminate agreement for ganaxolone in Europe - December 30th, 2024
- Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson - December 30th, 2024
- Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma - December 30th, 2024
- Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia - December 30th, 2024
- Hit Refresh in the New Year with Tilray's Premium Non-Alcohol Beverage Lineup - December 30th, 2024
- Biora Therapeutics Undertakes Chapter 11 Sale Process to Position Business for Future Growth - December 30th, 2024
- New Year, New Chill: Explore the Latest Cannabis Beverages from Solei, Mollo, and XMG - December 30th, 2024
Recent Comments